Objective: To investigate the changes in neutrophil / lymphocyte ratio and mean platelet volume levels, which are inflammatory markers, by treatment with infliximab in chronic resistant psoriasis patients treated with infliximab.

Patients and methods: The study was conducted with a total of 110 patients, including 50 patients with refractory psoriasis using infliximab and 60 healthy volunteers. Neutrophil lymphocyte ratio (NLR) and mean platelet volumes (MPV) of patients were calculated at the beginning of treatment. Infliximab was administered every 8 weeks after administration at 5 mg / kg doses at 0, 2, 6 and 14 weeks. At 12 months, blood samples were taken again for MPV and NLR levels.

Findings: Median NLR value before infliximab treatment was 2.32 (1.20–16.37). The median NLR at week 12 was 2.02 (1.0–6.88). There was a statistically significant difference between the two values ​​(p = 0.048). The mean MPV values ​​of the group of healthy volunteers were 9.85 ± 1.35 fL. The difference was statistically significant (p = 0.002) when the mean value of MPV before treatment was compared with that of patients with psoriasis, which was 9.0 ± 1.56 fL.

Conclusion: With infliximab therapy, inflammation is suppressed in psoriasis, an inflammatory disease, which is also reflected in inflammatory markers such as NLR and MPV.